Aptah Biosciences Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$3M
- Investors
-
6
Aptah Biosciences General Information
Description
Developer of novel RNA therapies designed for targeting cancer and neurodegenerative diseases. The company uses a process to create new synthetic and biological molecules based on deoxyribonucleic acid to achieve connection to a specific target in a few days rather than months, enabling medical professionals to reduce the time, costs, and risks of discovery and to make them widely available.
Contact Information
Website
www.aptah-bio.comCorporate Office
- 930 MBC Brittan Avenue
- Suite 370
- San Carlos, CA 94070
- United States
Corporate Office
- 930 MBC Brittan Avenue
- Suite 370
- San Carlos, CA 94070
- United States
Aptah Biosciences Timeline
Aptah Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 24-Mar-2025 | $3M | Completed | Clinical Trials - General | ||
| 6. Later Stage VC (Series A) | 14-Aug-2023 | Completed | Clinical Trials - General | |||
| 5. Accelerator/Incubator | 26-Aug-2021 | Completed | Clinical Trials - General | |||
| 4. Accelerator/Incubator | 14-Aug-2019 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 01-Jan-2019 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 1. Accelerator/Incubator | Completed | Clinical Trials - General |
Aptah Biosciences Patents
Aptah Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4652278-A1 | Polynucleotide compositions and methods for treatment of cancer | Pending | 18-Jan-2023 | ||
| US-20260085315-A1 | Polynucleotide compositions and methods for treatment of cancer | Pending | 18-Jan-2023 | ||
| WO-2024155740-A1 | Polynucleotide compositions and methods for treatment of cancer | Inactive | 18-Jan-2023 | ||
| EP-4652277-A1 | Polynucleotide compositions and methods for treatment of neurodegenerative diseases | Pending | 18-Jan-2023 | ||
| US-20260022377-A1 | Polynucleotide compositions and methods for treatment of neurodegenerative diseases | Pending | 18-Jan-2023 | C12N15/113 |
Aptah Biosciences Signals
Aptah Biosciences Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Financiadora de Estudos e Projetos | Government | |||
| MBC BioLabs | Accelerator/Incubator | Minority | ||
| Vesper (Biotechnology) | Accelerator/Incubator | Minority | ||
| Startup OutReach Brasil | Accelerator/Incubator | |||
| Biominas Brasil | Accelerator/Incubator |
Aptah Biosciences FAQs
-
When was Aptah Biosciences founded?
Aptah Biosciences was founded in 2018.
-
Where is Aptah Biosciences headquartered?
Aptah Biosciences is headquartered in San Carlos, CA.
-
What is the size of Aptah Biosciences?
Aptah Biosciences has 10 total employees.
-
What industry is Aptah Biosciences in?
Aptah Biosciences’s primary industry is Drug Discovery.
-
Is Aptah Biosciences a private or public company?
Aptah Biosciences is a Private company.
-
What is Aptah Biosciences’s current revenue?
The current revenue for Aptah Biosciences is .
-
How much funding has Aptah Biosciences raised over time?
Aptah Biosciences has raised $8M.
-
Who are Aptah Biosciences’s investors?
Financiadora de Estudos e Projetos, MBC BioLabs, Vesper (Biotechnology), Startup OutReach Brasil, and Biominas Brasil are 5 of 6 investors who have invested in Aptah Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process